Pre-made Bexmarilimab benchmark antibody ( Whole mAb, anti-STAB1 therapeutic antibody, Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faron’s wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab, targets the Clever-1 receptor, known to be expressed on immunosuppressive macrophages in the tumour microenvironment and circulating in soluble form, and which is capable of directly inhibiting T-cell activation.
| Products Name (INN Index) | Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody |
|---|---|
| INN Name | Bexmarilimab |
| Target | STAB1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Faron Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Solid tumours,Cancer,Immunocompromised infections,Pertussis,Tuberculosis |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | STAB1 |
| Package |
